I don't think that any big pharma would be willing to just do ONE indication for Brilacidin. That would make sense in light of CTIX's focusing on OM and UP first, because those studies are fast and cheap. Then with good results there, it would be much easier to strike a partnership/eventual licensing deal with a big pharma that has the deep pockets to do the much more expensive Brilacidin-ABSSSI study.

Just think of the complications if one big pharma had the rights for one kind of use for Bril, and another one had rights for another kind. For instance, what if someone got some Bril-OM and poured it on their skin lesions instead of using it as a mouthwash? And then doctors started prescribing a formulation off-label to use in some other way? What a mess! Easier for one company to own it all.

I would think that Prurisol would be the obvious candidate for the first deal. And given the great results so far, I'm pretty hopeful for that one.

Remember how we never used to talk about Prurisol very much, the focus was always on Kevetrin and then Brilacidin? That is going to be pretty funny if it does turn out to be the first deal.